• Explore /
  • Poster
  • / Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.

Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.

Abstract Poster

Authors

null

Kristen McCullough

Division of Hematology, Mayo Clinic, Rochester, MN

Kristen McCullough , Abhishek A Mangaonkar , Ashya R. Burgess , Aref Al-Kali , Hassan B. Alkhateeb , Kebede Begna , Naseema Gangat , Susan Michelle Geyer , William J. Hogan , Mark Robert Litzow , Kaaren Reichard , Antoine N Saliba , Mithun Vinod Shah , Alexandra P. Wolanskyj-Spinner , Mrinal Mahesh Patnaik

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Other Leukemia, Myelodysplastic Syndromes, and Allotransplant

Clinical Trial Registration Number

NCT05549661

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7089)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7089

Abstract #

TPS7089

Poster Bd #

211a

Abstract Disclosures

Similar Posters

First Author: Samuel John Harris

First Author: Antoine Hollebecque

First Author: Meredith Pelster

First Author: Lucia Masarova